ProblemEstablished rheumatology infusion patients still fall out of the schedule when renewals expire, payers force biosimilar switches, or pharmacy handoffs break. In a 225-patient cohort, 71% of infusible drugs needed PA and initially denied cases stretched to 50 days.
SolutionRenewalPulse Rheum is an AI workboard for continuation cases. It reads approval letters, labs, payer rules, and schedule data, then flags which next-dose patients are truly clear, which need a biosimilar exception, and which will miss the chair without intervention.
Market opportunityThe wedge sits inside a $64.35B RA-drugs market and a $50.63B ambulatory-infusion market. Clinics already accept software spend of $280-$729 per provider monthly, leaving room for a $499-$1,500 site-based rescue layer that protects recurring infusion revenue.